CD8A and COVID-19: Taken together, the above data suggest that early robust virus-specific CD4+ and CD8+ T cell responses control COVID-19 severity, whereas delayed and low-level antiviral adaptive immune responses, especially CD8+ T cells, are associated with worse clinical progression.